taletrectinib
innovent biologics,baoyuan biopharma,anheart therapeutics
['taletrectinib', 'innovent']
innovent and anheart jointly present updated phase 2 efficacy and safety data of taletrectinib (ros1-tki) at the 2022 american society of clinical oncology (asco) annual meeting 
World News Guru is completely free and offers a broad range of media content from a varied and extensive range of sources.